



INTELLECTUAL PROPERTY LAW

FACSIMILE**PHILADELPHIA**

One Liberty Place, 46th floor
Philadelphia, PA 19103
Phone: 215-568-3100
Fax: 215-568-3439

SEATTLE

999 Third Avenue, Suite 1606
Seattle, WA 98104
Phone: 206-332-1380
Fax: 206-624-7317

DATE: July 9, 2002

JOB CODE: 63841

OFFICIAL FAX**FAX RECEIVED**

Please deliver this and the following pages to:

JUL 10 2002

GROUP 1600

Name: Examiner Q. Li
Company/Firm: U.S.P.T.O.; Group Art Unit 1632
Telecopier No.: (703) 872-9307
Client/Matter No.: U.S. Serial No. 09/485,421; Our Docket No. UPVG-0191
Sender's Name: Paul K. Legaard
Pages to Follow: 13

If transmission is not complete, please call (215) 568-3100
COVER MESSAGE:

Attached is:

- 1) Amendment Transmittal Letter; and
- 2) Amendment and Request for Reconsideration.

PLEASE DELIVER TO EXAMINER Q. LI IMMEDIATELY!

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERY OF THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU.

Woodcock Washburn LLP
A Partnership Including Professional Corporations
www.woodcock.com

FAX RECEIVED

DOCKET NO.: UPVG-0191

- 4 -

JUL 10 2002

PATENT


sheet is provided in duplicate.

GROUP 1600

- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- ☐ The Foregoing Amount Due for Filing this Paper.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: July 9, 2002


Chad Ziegler
Registration No. 44,273

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2001 WW

DOCKET NO.: UPVG-0191

PATENT

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP NO. 1632**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mahalingam, Ayyavoo, Patel, Kleber-Emmons, and Welner

Serial No.: 09/485,421

Group Art Unit: 1632

Filed: October 5, 2000

Examiner: Q. Li

For: **FUNCTIONAL FRAGMENTS OF HIV-1 VPR PROTEIN AND METHODS
OF USING THE SAME**

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office to facsimile number (703) 872-9307 on the date shown below.

On July 9, 2002


Chad Ziegler Reg. No. 44,273

BOX AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND REQUEST FOR RECONSIDERATION

In response to the Office Action mailed April 9, 2002 in connection with the above-identified patent application, Applicant respectfully requests that the application be amended as follows.

In the Claims:

Please amend claims 1-4 and 7 to read as follows:

DOCKET NO.: UPVG-0191

PATENT

anticipate a claim, however, a prior art reference must disclose every feature of the claimed invention, either explicitly or inherently. *Glaxo v. Novopharm, Ltd.*, 334 U.S.P.Q.2d 1565 (Fed. Cir. 1995). Further, to serve as an anticipation when a reference is silent about the alleged inherent characteristic, such gap in the reference may be filled by extrinsic evidence. Such evidence, however, must make clear that the missing descriptive matter is necessarily (*i.e.*, always) present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill in the art. *In re Oelrich*, 40 U.S.P.Q. 323 (C.C.P.A. 1981); *Continental Can Co. USA Inc. v. Monsanto Co.*, 20 U.S.P.Q.2d 1746 (Fed. Cir. 1991). Inherency may not be established by probabilities or possibilities. *Id.* Further, the mere fact that a certain thing *may* result from a given set of circumstances is *not* sufficient. *Id.* Significantly, the Office Action has not established that the critical inherent characteristics are *necessarily* present in the Weiner reference.

Accordingly, Applicants respectfully request that the rejection under 35 U.S.C. § 102(b) be withdrawn.

II. The Claimed Inventions Are Not Obvious

Claims 1-11 are rejected under 35 U.S.C. § 103(a) as allegedly being unpatentable over the combination of the Weiner reference and U.S. Patent No. 6,005,004 (hereinafter, the "Katz reference") or U.S. Patent No. 6,232,295 (hereinafter, the "Kayyem reference"). The Office Action mistakenly asserts that it would have been *prima facie* obvious for one skilled in the art to modify the methods of the Weiner reference by adding a polycationic peptide sequence of the Katz or Kayyem references to the Vpr conjugate composition. Applicants traverse the rejection and respectfully request reconsideration because even if the cited references are combined, the claimed invention would not be produced.

The Office Action asserts that the Weiner reference does not teach a polycationic amino acid sequence. Therefore, the Office Action attempts to cure such a deficiency by citing the Katz and Kayyem references. For the sake of brevity, the statements made above regarding the Weiner reference are incorporated herein by reference in their entirety. The Weiner reference does not teach or suggest fragments of Vpr comprising amino acids 17-36 and/or 59-84, as recited in Applicants'

DOCKET NO.: UPVG-0191**PATENT****IV. Conclusion**

In view of the foregoing, Applicants respectfully submit that the claims are in condition for allowance. An early notice of the same is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at (215) 564-8906 if there are any questions regarding Applicants' claimed invention. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,



Chad Ziegler
Registration No. 44,273

Date: July 9, 2002

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

DOCKET NO.: UPVG-0191**PATENT****VERSION WITH MARKINGS TO SHOW CHANGES MADE****In the Claims:**

Claims 1-4 and 7 have been amended as follows:

1. (Amended twice) A conjugated composition comprising[:]
a fragment of HIV-1 Vpr comprising amino acid sequence 17-36 and/or 59-84 [or a non-HIV-1 Vpr protein comprising amino acids amino acids 17-36 and/or 59-84 of HIV-1 Vpr protein] conjugated to a therapeutic compound.
2. (Amended) The conjugated composition of claim 1 wherein said fragment of HIV-1 Vpr [or said non-HIV-1 Vpr protein] further comprises a polycationic amino acid sequence.
3. (Amended) The conjugated composition of claim 1 wherein said therapeutic compound is a DNA vaccine plasmid conjugated to said fragment of HIV-1 Vpr [or said non-HIV-1 Vpr protein] by ionic bonds.
4. (Amended) The conjugated composition of claim 1 wherein said fragment of HIV-1 Vpr [or said non-HIV-1 Vpr protein] further comprises a polycationic amino acid sequence and said therapeutic compound is a nucleic acid molecule which is conjugated to said polycationic amino acid sequence by ionic bonds.
7. (Amended) A method of delivering a compound to the nucleus of a cell comprising the step of:
contacting said cell with a conjugated compound that is either said compound conjugated to a fragment of HIV-1 Vpr protein comprising amino acids 17-36 and/or 59-84 [or said compound conjugated to a non-HIV-1 Vpr protein comprising amino acids 17-36 and/or 59-84 of HIV-1 Vpr protein]; wherein said conjugated compound is taken up by said cell and localized to the nucleus of said cell.